A Phase 4 interventional study of Insulin glargine, 300 U/ml and Insulin glargine, 100 U/ml in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 427 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment of the 175 interventional ones that give a count, is one of 14 that started in 2015, is one of 103 in phase 4, and was the 124th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 14 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,304 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 5th largest by enrollment of the 178 interventional ones that give a count, is one of 11 that started in 2015, is one of 75 in phase 4, and was the 131st registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Demonstrate clinical benefit of Toujeo in achieving individualized Healthcare Effectiveness Data and Information Set (HEDIS) glycated hemoglobin (HbA1c) targets (\<8% if age >=65 years or with defined comorbidities or otherwise \<7%) at 6 months without documented symptomatic (Blood Glucose \<=70 mg/deciliter [mg/dL]) and/or severe hypoglycemia at any time of day from baseline to 6 months in uncontrolled insulin naive participants with type 2 diabetes initiating basal insulin therapy in a real world setting.
Secondary Objectives:
Compare Toujeo to other commercially available basal insulins at 6 months after initiating insulin therapy in a real world setting in terms of:
The total study duration per patient will be up to 53 weeks, consisting of a 1-week screening period at the site, a 26-week treatment period, and a 26-week extension period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Toujeo® (Insulin glargine, 300 units per millilitre \[U/mL\]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.
Drug: Insulin glargine, 300 U/ml · Drug: Background Therapy
Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.
Drug: Insulin glargine, 100 U/ml · Drug: Insulin detemir · Drug: Background Therapy
Drug page: Insulin Glargine
Pharmaceutical form: solution Route of administration: subcutaneous
Also known as: Toujeo
Drug page: Insulin Glargine
Pharmaceutical form: solution Route of administration: subcutaneous
Also known as: Lantus
Pharmaceutical form: solution Route of administration: subcutaneous
Also known as: Levemir
Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia
HEDIS criteria: Individualized HbA1c target \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=70 milligrams per deciliter (mg/dL) (\<=3.9 millimoles per litre \[mmol/L\]). Analysis was performed using all post-baseline data available on the 6 month randomized period (defined as time from randomization up to Day 180 or discontinuation date, whichever comes earlier).
Time frame: Baseline to Month 6
Change From Baseline in HbA1c at Month 6 and Month 12
Change in HbA1c was calculated by subtracting baseline value from Month 6 and Month 12 values. Adjusted Least Squares (LS) means and Standard Errors (SE) were obtained using Mixed Effect Model with Repeated Measures (MMRM ) with fixed categorical effects of treatment arm, visit, treatment arm-by-visit interaction, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline HbA1c (as continuous) and baseline HbA1c-by-visit interaction.
Time frame: Baseline, Month 6, Month 12
Treatment Persistence Measured by Medication Possession Ratio (MPR)
Treatment persistence was determined based on vendor claims database that would be responsible for managing and administration of the study drugs. Medication use was assessed by MPR and persistence measures based on data collected by the smart card vendor (date of fill or refill and quantity of medication dispensed for 30-day supply). The MPR was assessed based on total number of days of supply divided by the total number of days in 6 or 12 months period.
Time frame: At Month 6 and Month 12
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period
HEDIS criteria for Individualized HbA1c target: \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (3.0 mmol/L).
Time frame: Baseline to Month 6
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period
HEDIS criteria for Individualized HbA1c target: \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (\<=70 mg/dL) and \< 3.0 mmol/L (\< 54 mg/dL).
Time frame: Baseline to Month 12
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12
Change in FPG was calculated by subtracting baseline value from Month 6 and Month 12 values. Adjusted LS means and SE were obtained using MMRM model with fixed categorical effects of treatment arm, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline FPG (as continuous) and baseline FPG-by-visit interaction.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Body Weight at Month 6 and Month 12
Adjusted LS means and SE were obtained using MMRM model with fixed categorical effects of treatment arm, visit, treatment arm-by-visit interaction, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline weight (as continuous) and baseline weight-by-visit interaction.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Basal Insulin Dose at Month 6 and Month 12
Change in basal insulin dose was calculated by subtracting baseline value from Month 6 and Month 12 values.
Time frame: Baseline, Month 6, Month 12
Percentage of Responders (Participants and Provider) Who Reported "Excellent" or "Good" Responses to Global Effectiveness Scale (GES) Question at Month 6, and Month 12
Participant and Physician (Provider) reported GES for this diabetes study. The GES assessed impact of treatment on scale ranges as: excellent (complete control of diabetes), good (marked improvement of diabetes), moderate (discernible, but limited improvement in diabetes), poor (no appreciable change in diabetes), or worsening of condition (worsening of diabetes). There was no score expressed by numbers and no change measured over the time of the study. Percentage of participants and providers who reported "excellent" or "good" on the GES at Month 6 and Month 12 are reported here.
Time frame: At Month 6, Month 12
Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs) at Baseline, Month 6, Month 12
DTSQs is a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consists of 8 items, each answered on a Likert scale of 0 to 6. Responses of 6 questions (Items 1, 4, 5, 6, 7 and 8) were summarized to derive total treatment satisfaction score, such that a higher score was indicative of better satisfaction. Total treatment satisfaction score is the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (improvement in treatment satisfaction). Item 2 and Item 3 scores were used for hyperglycemia perception and hypoglycemia perception respectively, where lower scores indicated better health outcome. Perceived frequency of hyperglycemia score (Item 2) and perceived frequency of hypoglycemia score (Item 3) range from 0 (none of the time) to 6 (most of time), where lower scores indicated more satisfaction/better health outcome.
Time frame: At Baseline, Month 6, Month 12
Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) at Month 12
DTSQc version evaluates the change in treatment satisfaction at Month 12 as compared to the start of the study . It consists of 8 items, each answered on a Likert scale from -3 to +3. The sum of treatment satisfaction scores (items 1, 4, 5, 6, 7,and 8) ranged from score -18 (deterioration in treatment satisfaction) to +18 (improvement in treatment satisfaction). Perceived frequency of hypoglycemia and perceived frequency of hyperglycemia score ranges from score -3 (fewer problems) to +3 (more problems).
Time frame: At Month 12
Percentage of Participants With Hospitalizations, Emergency Rooms and Specialty Visits From Baseline to Month 6 and Month 12
Percentage of participants with hospitalizations, emergency room visits, and specialty visits during the 6-month and 12-month randomized period were reported. The 12-month randomized period was defined as the time from randomization up to Day 365 or discontinuation date, whichever comes earlier.
Time frame: From Baseline to Month 6 and Month 12
Percentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period
Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (\<=3.9 mmol/L) or \<54 mg/dL (3.0 mmol/L).
Time frame: Up to Month 6 and Month 12
The study was conducted at 427 sites in 2 countries. A total of 4989 participants were screened between 16 June 2015 and 14 July 2017, of which 1684 were screen failures. Screen failures were mainly due to inclusion criteria not met.
| Milestone | Toujeo | Standard of Care |
|---|---|---|
| Started | 1651 | 1653 |
| Treated | 1632 | 1626 |
| Safety population | 1637 | 1621 |
| Completed | 1405 | 1355 |
| Not completed | 246 | 298 |
| Withdrew: Randomized but not treated | 19 | 27 |
| Withdrew: Adverse event | 43 | 42 |
| Withdrew: Lack of efficacy | 4 | 9 |
| Withdrew: Participant decision:discontinue insulin | 41 | 43 |
| Withdrew: Hypoglycemia | 2 | 1 |
| Withdrew: Investigator's decision | 23 | 19 |
| Withdrew: Lost to follow-up | 53 | 61 |
| Withdrew: Physician decision | 6 | 5 |
| Withdrew: Sponsor decision | 13 | 25 |
| Withdrew: Withdrawal by subject | 40 | 63 |
| Withdrew: Other than specified above | 2 | 3 |
HEDIS criteria: Individualized HbA1c target \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=70 milligrams per deciliter (mg/dL) (\<=3.9 millimoles per litre \[mmol/L\]). Analysis was performed using all post-baseline data available on the 6 month randomized period (defined as time from randomization up to Day 180 or discontinuation date, whichever comes earlier).
| percentage of participants | Toujeo | Standard of Care |
|---|---|---|
| Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia | 31.3 | 27.9 |
Change in HbA1c was calculated by subtracting baseline value from Month 6 and Month 12 values. Adjusted Least Squares (LS) means and Standard Errors (SE) were obtained using Mixed Effect Model with Repeated Measures (MMRM ) with fixed categorical effects of treatment arm, visit, treatment arm-by-visit interaction, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline HbA1c (as continuous) and baseline HbA1c-by-visit interaction.
| percentage of HbA1c | Toujeo | Standard of Care |
|---|---|---|
| Month 6 | -1.40 ± 0.030 | -1.36 ± 0.030 |
| Month 12 | -1.29 ± 0.034 | -1.24 ± 0.034 |
Treatment persistence was determined based on vendor claims database that would be responsible for managing and administration of the study drugs. Medication use was assessed by MPR and persistence measures based on data collected by the smart card vendor (date of fill or refill and quantity of medication dispensed for 30-day supply). The MPR was assessed based on total number of days of supply divided by the total number of days in 6 or 12 months period.
| Medication Possession ratio | Toujeo | Standard of Care |
|---|---|---|
| Month 6 | 62.06 ± 26.98 | 63.14 ± 28.42 |
| Month 12 | 58.21 ± 28.87 | 57.82 ± 29.97 |
HEDIS criteria for Individualized HbA1c target: \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (3.0 mmol/L).
| percentage of participants | Toujeo | Standard of Care |
|---|---|---|
| Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period | 37.3 | 34.3 |
HEDIS criteria for Individualized HbA1c target: \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (\<=70 mg/dL) and \< 3.0 mmol/L (\< 54 mg/dL).
| percentage of participants | Toujeo | Standard of Care |
|---|---|---|
| Month 12: <=70 mg/dL | 26.1 | 23.7 |
| Month 12: <54 mg/dL | 33.0 | 29.5 |
Change in FPG was calculated by subtracting baseline value from Month 6 and Month 12 values. Adjusted LS means and SE were obtained using MMRM model with fixed categorical effects of treatment arm, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline FPG (as continuous) and baseline FPG-by-visit interaction.
| mg/dL | Toujeo | Standard of Care |
|---|---|---|
| Month 6 | -48.9 ± 1.56 | -50.4 ± 1.58 |
| Month 12 | -48.0 ± 1.66 | -47.3 ± 1.69 |
Adjusted LS means and SE were obtained using MMRM model with fixed categorical effects of treatment arm, visit, treatment arm-by-visit interaction, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline weight (as continuous) and baseline weight-by-visit interaction.
| kilogram (kg) | Toujeo | Standard of Care |
|---|---|---|
| Month 6 | 1.02 ± 0.109 | 1.14 ± 0.110 |
| Month 12 | 1.51 ± 0.140 | 1.40 ± 0.142 |
Change in basal insulin dose was calculated by subtracting baseline value from Month 6 and Month 12 values.
| Unit/kg (U/kg) | Toujeo | Standard of Care |
|---|---|---|
| Month 6 | 0.179 ± 0.212 | 0.183 ± 0.218 |
| Month 12 | 0.222 ± 0.232 | 0.224 ± 0.241 |
Participant and Physician (Provider) reported GES for this diabetes study. The GES assessed impact of treatment on scale ranges as: excellent (complete control of diabetes), good (marked improvement of diabetes), moderate (discernible, but limited improvement in diabetes), poor (no appreciable change in diabetes), or worsening of condition (worsening of diabetes). There was no score expressed by numbers and no change measured over the time of the study. Percentage of participants and providers who reported "excellent" or "good" on the GES at Month 6 and Month 12 are reported here.
| percentage of responders | Toujeo | Standard of Care |
|---|---|---|
| Percentage of Participants: Month 6 | 67.2 | 65.6 |
| Percentage of Providers: Month 6 | 62.1 | 57.7 |
| Percentage of Participants: Month 12 | 64.7 | 64.2 |
| Percentage of Providers: Month 12 | 58.8 | 56.3 |
DTSQs is a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consists of 8 items, each answered on a Likert scale of 0 to 6. Responses of 6 questions (Items 1, 4, 5, 6, 7 and 8) were summarized to derive total treatment satisfaction score, such that a higher score was indicative of better satisfaction. Total treatment satisfaction score is the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (improvement in treatment satisfaction). Item 2 and Item 3 scores were used for hyperglycemia perception and hypoglycemia perception respectively, where lower scores indicated better health outcome. Perceived frequency of hyperglycemia score (Item 2) and perceived frequency of hypoglycemia score (Item 3) range from 0 (none of the time) to 6 (most of time), where lower scores indicated more satisfaction/better health outcome.
| score on a scale | Toujeo | Standard of Care |
|---|---|---|
| Total treatment satisfaction score:Baseline | 26.5 ± 7.0 | 26.4 ± 7.1 |
| Total treatment satisfaction score: Month 6 | 31.0 ± 5.5 | 31.1 ± 5.3 |
| Total treatment satisfaction score: Month 12 | 30.9 ± 6.0 | 30.7 ± 6.1 |
| Perceived frequencyof hyperglycemia score:Baseline | 4.3 ± 1.7 | 4.3 ± 1.7 |
| Perceived frequency of hyperglycemia score:Month 6 | 2.8 ± 1.7 | 2.8 ± 1.7 |
| Perceived frequency of hyperglycemia score:Month12 | 2.6 ± 1.7 | 2.6 ± 1.7 |
| Perceived frequency of hypoglycemia score:Baseline | 0.9 ± 1.4 | 0.8 ± 1.3 |
| Perceived frequency of hypoglycemia score: Month 6 | 0.9 ± 1.3 | 1.0 ± 1.4 |
| Perceived frequency of hypoglycemia score:Month 12 | 0.9 ± 1.3 | 1.0 ± 1.4 |
DTSQc version evaluates the change in treatment satisfaction at Month 12 as compared to the start of the study . It consists of 8 items, each answered on a Likert scale from -3 to +3. The sum of treatment satisfaction scores (items 1, 4, 5, 6, 7,and 8) ranged from score -18 (deterioration in treatment satisfaction) to +18 (improvement in treatment satisfaction). Perceived frequency of hypoglycemia and perceived frequency of hyperglycemia score ranges from score -3 (fewer problems) to +3 (more problems).
| score on a scale | Toujeo | Standard of Care |
|---|---|---|
| Total satisfaction score | 13.81 ± 0.15 | 13.79 ± 0.15 |
| Perceived frequency of hyperglycemia score | 0.14 ± 0.05 | 0.21 ± 0.05 |
| Perceived frequency of hypoglycemia | -0.82 ± 0.05 | -0.82 ± 0.05 |
Percentage of participants with hospitalizations, emergency room visits, and specialty visits during the 6-month and 12-month randomized period were reported. The 12-month randomized period was defined as the time from randomization up to Day 365 or discontinuation date, whichever comes earlier.
| percentage of participants | Toujeo | Standard of Care |
|---|---|---|
| Hospitalizations: Month 6 | 8.1 | 7.5 |
| Emergency Room Visits: Month 6 | 11.3 | 10.3 |
| Specialty Visits: Month 6 | 78.3 | 74.0 |
| Hospitalizations: Month 12 | 9.1 | 8.0 |
| Emergency Room Visits: Month 12 | 12.7 | 11.1 |
| Specialty Visits: Month 12 | 80.1 | 75.9 |
Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (\<=3.9 mmol/L) or \<54 mg/dL (3.0 mmol/L).
| percentage of participants | Toujeo | Standard of Care |
|---|---|---|
| Any hypoglycemia: Any time: Month 6 | 28.9 | 30.4 |
| Any hypoglycemia: Nocturnal: Month 6 | 8.9 | 10.0 |
| Any hypoglycemia: Any time: Month 12 | 39.1 | 41.8 |
| Any hypoglycemia: Nocturnal: Month 12 | 13.6 | 14.9 |
| Severe hypoglycemia: Any time: Month 6 | 1.0 | 1.0 |
| Severe hypoglycemia:Nocturnal: Month 6 | 0.5 | 0.6 |
| Documented Symptomatic <=70 mg/dL:Any time:Month 6 | 13.9 | 14.9 |
| Documented Symptomatic <54 mg/dL:Any time:Month 6 | 3.6 | 3.1 |
| Documented Symptomatic <=70mg/dL:Nocturnal:Month 6 | 4.5 | 5.6 |
| Documented Symptomatic <54 mg/dL:Nocturnal:Month 6 | 0.8 | 0.8 |
| Severe hypoglycemia: Any time: Month 12 | 1.2 | 1.9 |
| Severe hypoglycemia:Nocturnal: Month 12 | 0.5 | 0.7 |
| Documented Symptomatic<=70 mg/dL:Any time:Month 12 | 19.9 | 20.8 |
| Documented Symptomatic <54 mg/dL:Any time:Month 12 | 5.6 | 5.6 |
| Documented Symptomatic<=70mg/dL:Nocturnal:Month 12 | 6.5 | 8.3 |
| Documented Symptomatic <54mg/dL:Nocturnal:Month 12 | 1.2 | 1.7 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the end of study (12 months) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Toujeo | 7/1,637 (0.4%) | 161/1,637 (9.8%) | 0/1,637 (0%) |
| Standard of Care Basal Insulin | 4/1,621 (0.2%) | 165/1,621 (10.2%) | 0/1,621 (0%) |
| Event | Toujeo | Standard of Care Basal Insulin |
|---|---|---|
| PneumoniaInfections and infestations | 10/1637 | 14/1621 |
| Coronary Artery DiseaseCardiac disorders | 10/1637 | 9/1621 |
| Non-Cardiac Chest PainGeneral disorders | 10/1637 | 5/1621 |
| Acute Kidney InjuryRenal and urinary disorders | 8/1637 | 9/1621 |
| SepsisInfections and infestations | 4/1637 | 8/1621 |
| Acute Myocardial InfarctionCardiac disorders | 8/1637 | 4/1621 |
| Atrial FibrillationCardiac disorders | 8/1637 | 6/1621 |
| CellulitisInfections and infestations | 2/1637 | 7/1621 |
| Angina PectorisCardiac disorders | 6/1637 | 3/1621 |
| Cardiac Failure CongestiveCardiac disorders | 6/1637 | 4/1621 |
Analysis was performed on all randomized participants. Participants belonging to more than one race, have been reported under each applicable category.
| Age, Continuous(years) | Toujeo | Standard of Care | Total |
|---|---|---|---|
| Mean | 59.4 ± 10.8 | 59.1 ± 11.0 | 59.3 ± 10.9 |
| Sex: Female, Male(Participants) | Toujeo | Standard of Care | Total |
|---|---|---|---|
| Female | 747 | 731 | 1478 |
| Male | 904 | 922 | 1826 |
| Ethnicity (NIH/OMB)(Participants) | Toujeo | Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 286 | 305 | 591 |
| Not Hispanic or Latino | 1365 | 1348 | 2713 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Toujeo | Standard of Care | Total |
|---|---|---|---|
| Caucasian/White | 1283 | 1299 | 2582 |
| Black | 262 | 238 | 500 |
| Asian/Oriental | 83 | 95 | 178 |
| American Indian or Alaska Native | 15 | 12 | 27 |
| Native Hawaiian or other Pacific Islander | 6 | 4 | 10 |
| Other | 12 | 14 | 26 |
| Region of Enrollment(Participants) | Toujeo | Standard of Care | Total |
|---|---|---|---|
| Canada | 82 | 85 | 167 |
| United States | 1569 | 1568 | 3137 |
| Body Mass Index (BMI)(kg/m^2) | Toujeo | Standard of Care | Total |
|---|---|---|---|
| Mean | 33.85 ± 7.14 | 33.70 ± 7.29 | 33.77 ± 7.22 |
| Duration of Type 2 Diabetes Mellitus(years) | Toujeo | Standard of Care | Total |
|---|---|---|---|
| Mean | 11.43 ± 7.43 | 11.16 ± 7.31 | 11.30 ± 7.37 |
| Baseline glycated hemoglobin (HbA1c)(percentage of HbA1c) | Toujeo | Standard of Care | Total |
|---|---|---|---|
| Mean | 9.1 ± 0.8 | 9.2 ± 0.8 | 9.2 ± 0.8 |
Showing the first 100 of 427 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Mar 2018, 32 months.
Results were first posted in May 2019, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 32 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine